Flexion Therapeutics (NASDAQ:FLXN) is part of the seemingly never-ending wave of biotechnology companies going public this year, and raised $67 million in its February debut. The company focuses on drugs for pain, and its lead candidate FX006 is a sustained-release version of the routinely used steroid triamcinolone acetonide (TCA) for the treatment of pain associated with moderate to severe osteoarthritis (NYSE:OA) of the knee. Flexion will seek a 505(b)(2) pathway for the development of FX006, which comes with several advantages to the company and investors alike. This potentially accelerated development, some encouraging initial data, and the cash to fund new trials suggest that Flexion could rally in 2014.
505(b)(2) Pathway is the Key
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|